Does HRT Cause Joint Pain or Help Alleviate It?

Hormone replacement therapy generally helps with joint pain rather than causing it, but the picture is more mixed than either fans or critics of HRT suggest. The largest randomized trial on the topic, from the Women’s Health Initiative, found that estrogen modestly reduced joint pain frequency in postmenopausal women after one and three years of use. Yet a recent systematic review pooling data from multiple studies found no overall effect of HRT on generalized musculoskeletal pain. Whether HRT helps your joints depends on which formulation you take, which joints hurt, and possibly even your genetic makeup.

Why Joints Hurt More During and After Menopause

Before considering whether HRT helps or harms, it is worth understanding how large the problem actually is. More than 70% of women experience musculoskeletal symptoms during the transition from perimenopause to postmenopause, and about a quarter are disabled by them.¹ A systematic review of over 93,000 women found that about four in ten premenopausal women reported muscle or joint pain, compared with roughly six in ten perimenopausal and postmenopausal women, representing about a 40% increase in risk once the menopausal transition begins.² In longitudinal research tracking women over time, aches and stiff joints were actually the most commonly reported menopausal symptom, ahead of hot flashes.³

The underlying driver is the drop in estrogen. Estrogen receptors are found throughout joint cartilage in both women and men, across multiple species.⁴ When circulating estrogen falls, cartilage loses a protective signal it has relied on for decades. Estrogen also influences inflammatory pathways: in postmenopausal women, HRT has been shown to lower levels of TNF-alpha and IL-1-beta, two inflammatory molecules that drive joint pain and cartilage breakdown.⁵ This combination of lost cartilage support and increased inflammation helps explain why joint aches hit so many women around menopause, and why replacing estrogen could theoretically reverse some of that damage.

What the Largest Trial Found

The strongest evidence on HRT and joint pain comes from the Women’s Health Initiative (WHI), which randomized thousands of postmenopausal women to estrogen or placebo. After one year, women taking estrogen alone had joint pain less frequently than those on placebo (about 76% versus 79% reporting pain). That gap persisted through year three, when pain frequency was roughly 74% in the estrogen group versus 80% in the placebo group.⁶ The women on placebo saw their pain scores rise over time, while those on estrogen stayed flat, suggesting that estrogen was not just masking pain but preventing the worsening that typically accompanies aging.

That said, the absolute differences were small. A shift from 79% to 76% experiencing pain means roughly three in a hundred women were spared by estrogen. The researchers described the benefit as “modest but sustained.” And there was an unexpected wrinkle: joint swelling frequency was actually slightly higher in the estrogen group than in the placebo group (about 42% versus 40%). When analyses accounted for how well participants stuck to their assigned treatment, the pain reduction became stronger, but the swelling difference faded.⁷ So estrogen seems to help with pain more than it helps with the physical signs of joint inflammation.

Why the Meta-Analysis Tells a Different Story

If you only read the WHI data, you might conclude that HRT reliably reduces joint pain. But a recent systematic review and meta-analysis pooling results across multiple studies found no overall effect of ever using HRT versus never using it on generalized musculoskeletal pain. The pooled risk ratio came out to essentially 1.0, meaning HRT users and non-users reported pain at the same rate.⁸ The reviewers also attempted to analyze osteoarthritis and rheumatoid arthritis outcomes separately but found so much variation between studies that they could not meaningfully pool those results.

How can a large randomized trial show a benefit while a meta-analysis shows nothing? Several factors likely explain the gap. The meta-analysis grouped together women who used HRT for different durations, at different doses, with different formulations, and at different points in their menopausal transition. It also relied heavily on observational studies, where women who choose HRT may differ in important ways from those who do not. The WHI, by contrast, was a controlled experiment comparing estrogen alone to a placebo in a specific population. The meta-analysis authors themselves highlighted the “substantial heterogeneity” in the field and stressed that bespoke studies are needed before drawing firm conclusions.

Estrogen Alone Versus Estrogen Plus Progestin

One of the most striking findings in this area is that estrogen alone and combination therapy (estrogen plus progestin) appear to have different effects on joints. In the WHI data on joint replacement surgery, women taking estrogen alone had a lower rate of arthroplasty overall compared with placebo, with a hazard ratio of 0.84. But women taking estrogen plus progestin had no reduction at all, with a hazard ratio of 0.99.⁹

This difference matters clinically. Women who still have a uterus typically take combined therapy to protect against endometrial cancer, while those who have had a hysterectomy can take estrogen alone. The data suggest that the addition of progestin may blunt estrogen’s joint-protective effects. Researchers are still working out why, but one possibility is that certain progestins interact with inflammatory pathways differently than estrogen does, partially counteracting its anti-inflammatory action in joint tissues.

What Happens to Cartilage Itself

Pain is one outcome, but structural changes to the joint are another. Some of the more intriguing evidence involves cartilage degradation markers measured in blood and urine. Women on HRT had roughly half the level of a specific cartilage breakdown marker (CTX-II) compared with age-matched women not on HRT, a statistically significant difference.¹⁰ Lower levels of this marker suggest less active cartilage destruction.

However, when researchers have looked at cartilage thickness on imaging, the picture is less clear. A recent systematic review and meta-analysis of studies using MRI-based cartilage thickness measurements and other structural markers found non-significant trends toward greater cartilage loss in estrogen-deficient women, but nothing conclusive.¹¹ An earlier review concluded that HRT may not provide symptomatic relief in osteoarthritis but could interfere with its long-term structural progression, particularly in the lower limbs.¹² In other words, estrogen might slow the disease under the surface even when you do not feel noticeably better day to day.

The Rebound Problem When You Stop

One commonly reported experience is that joint pain gets worse after stopping HRT, sometimes worse than before starting. This is consistent with what researchers have documented. A similar pattern of sudden joint pain follows withdrawal from HRT and also occurs with aromatase inhibitors, drugs used in breast cancer treatment that aggressively suppress estrogen production.¹³ After the WHI trial ended and participants stopped their assigned treatments, women who had been on estrogen plus progestin reported higher rates of pain and stiffness than those who had been on placebo, suggesting either a rebound effect or simply the unmasking of symptoms that HRT had been suppressing.¹⁴

This rebound is worth knowing about before starting HRT for joint pain. If you plan to take it temporarily and then stop, the return of symptoms can feel like the treatment made things worse, when in reality you are experiencing the same estrogen-withdrawal effect that drove the original pain. Gradual tapering rather than abrupt cessation is often recommended, though large trials specifically testing tapering strategies for joint outcomes are lacking.

How Aromatase Inhibitors Confirm the Estrogen Connection

Some of the best indirect evidence that estrogen protects joints comes from the experience of breast cancer patients taking aromatase inhibitors. These drugs work by blocking the enzyme that produces estrogen throughout the body, driving levels far lower than natural menopause does. The resulting joint pain is so common and so severe that it has its own name: aromatase inhibitor-associated musculoskeletal syndrome, or AIMSS.¹⁵ Joint stiffness and aching are the leading reason women discontinue aromatase inhibitor therapy.¹⁶

The AIMSS experience essentially runs the estrogen-and-joints experiment in reverse: instead of adding estrogen and watching what happens, you remove it aggressively and see what breaks. The answer is that joints hurt, confirming that estrogen is doing meaningful protective work in joint tissues. Of course, women taking aromatase inhibitors cannot simply add HRT back, as that would defeat the cancer treatment. But the AIMSS phenomenon helps explain why menopausal joint pain is real and biologically driven, not imagined.

Estrogen and Joint Stiffness in Younger Women

The relationship between estrogen and joints is not exclusive to menopause. Research in female athletes has found that ankle joint stiffness, knee joint stiffness, and leg stiffness all varied with estrogen levels across the menstrual cycle, with higher estrogen associated with greater mechanical stiffness in those joints.¹⁷ Hip and vertical stiffness did not show the same association, suggesting that estrogen’s influence varies by joint location. This is consistent with the broader observation that different joints respond differently to hormonal changes, and it may help explain why some menopausal women feel pain primarily in their hands or knees while others feel it in their hips.

Genetics May Explain Why HRT Helps Some Women More Than Others

Not everyone responds to estrogen the same way, and genetics appear to play a role. Variations in the genes encoding estrogen receptors have been linked to both the risk of developing joint pain and the severity of musculoskeletal symptoms during estrogen-modifying treatments. Certain variants in the ESR1 gene, which encodes a major estrogen receptor, were associated with the risk of developing temporomandibular disorders and chronic joint pain.¹⁸

In breast cancer patients on aromatase inhibitors, specific ESR1 gene variants predicted who would develop the worst joint symptoms. Women carrying certain genotypes had significantly less severe hand and knee/hip symptoms than those with other variants.¹⁹ If this applies to HRT as well, and the biological logic suggests it would, then some women may be genetically primed to benefit from estrogen replacement at the joint level while others are not. This could partially explain the conflicting results between studies: the average effect across a genetically diverse population may wash out, even though a subset of women experiences substantial relief.

Does HRT Reduce the Need for Joint Replacement?

Joint replacement surgery for severe osteoarthritis is about as hard an endpoint as you can get. If HRT truly protects joints, you would expect long-term users to need fewer replacements. The evidence here is genuinely conflicting. As noted earlier, the WHI estrogen-alone arm showed a borderline reduction in arthroplasty rates. But a large nationwide cohort study of over one million postmenopausal women found the opposite: HRT use was associated with an increased risk of knee replacement surgery for severe osteoarthritis, and HRT use for more than five years was associated with higher risk of hip replacement as well.²⁰

These findings seem contradictory, but they can coexist. The observational cohort may reflect confounding: women who start HRT might be more health-engaged, more likely to seek surgical treatment, or more symptomatic to begin with. The WHI trial, being randomized, avoids that problem but has limited follow-up. It is also possible that HRT reduces pain enough to keep women active, which is good for health but adds mechanical load to joints already showing cartilage wear. Researchers have not settled this question. If you are considering HRT specifically to avoid joint replacement down the road, the evidence does not currently support that as a reliable expectation.

Exercise, HRT, and Body Weight

A randomized trial specifically tested whether combining HRT with a structured exercise program would help postmenopausal women with greater trochanteric pain syndrome, a common cause of lateral hip pain. The combination of HRT and exercise produced significantly better outcomes than exercise alone or HRT alone, but only in women with a BMI under 25.²¹ In women with higher BMI, the benefits were not significant. This fits with other evidence that body weight modifies the relationship between hormones and joints: excess weight increases mechanical stress on joints while also altering hormone metabolism in fat tissue.

High BMI has been independently identified as a risk factor for reporting bothersome joint pain during the menopausal transition.³ The practical implication is that HRT alone is unlikely to solve menopausal joint pain if weight is a contributing factor. Exercise and weight management remain essential regardless of whether you use HRT.

Oral Versus Transdermal Delivery

How estrogen enters your body may matter for joint outcomes. Oral estrogen passes through the liver first, which triggers production of inflammatory markers like C-reactive protein. Transdermal estrogen (patches or gels) bypasses the liver and has less pronounced effects on these inflammatory markers.²² Since joint pain involves inflammation, it is plausible that the route of delivery could influence how much joint benefit you get. Transdermal estrogen avoids triggering the liver-based inflammatory response that oral estrogen creates, which is a theoretical advantage for joint health. However, head-to-head trials comparing oral and transdermal HRT specifically for joint outcomes are lacking. Most of the large trials used oral estrogen, so the joint-pain evidence base is weighted toward that formulation.

Hand Osteoarthritis and Menopause

Hand osteoarthritis deserves special mention because its prevalence spikes sharply around menopause, particularly in women. The timing is so striking that researchers have long suspected a direct hormonal link. Whether HRT helps with symptomatic hand osteoarthritis specifically remains an open question, with critical gaps in the evidence identified in review papers on the topic.²³ A recent study in Japanese perimenopausal women found that menopausal hormone therapy showed better results than complementary and alternative medicine approaches for symptomatic hand osteoarthritis.²⁴ Hand osteoarthritis is an area where the gap between patient need and available evidence is especially wide: many women develop painful, stiff fingers right around menopause, and the research specifically testing HRT for this condition remains thin.

Rheumatoid Arthritis Is a Separate Question

If you have rheumatoid arthritis rather than the garden-variety aching and stiffness of menopausal arthralgia or osteoarthritis, the evidence on HRT is different. In the WHI trial, postmenopausal hormone therapy did not significantly reduce the risk of developing rheumatoid arthritis, nor did it meaningfully improve symptoms in women who already had it. There was a trend toward reduced risk of developing RA, but it was not statistically significant. Joint pain scores showed a non-significant improvement, and joint swelling did not improve at all.²⁵ Rheumatoid arthritis is an autoimmune condition driven by different pathways than the estrogen-related joint changes of menopause, so the lack of a clear HRT benefit makes biological sense.

When HRT Could Make Joint Symptoms Worse

Although the overall direction of evidence points toward modest benefit, there are scenarios where HRT could genuinely worsen joint symptoms. The slight increase in joint swelling seen in the WHI estrogen-alone trial is one example. Estrogen promotes fluid retention, and some women notice puffier, stiffer joints early in HRT treatment, particularly in the hands and fingers. This typically settles within a few months as the body adjusts, but for women who already have significant joint swelling from osteoarthritis, the early phase of HRT can feel like a step backward.

Additionally, some progestins used in combination therapy can have androgenic or glucocorticoid-like effects that affect joints and tendons differently than estrogen alone. As the WHI data on joint replacement showed, combination therapy did not reproduce the benefit seen with estrogen alone. If your primary motivation for starting HRT is joint pain and you are on a combined regimen, the joint benefit may be smaller than you expect, or absent. Discussing the specific progestin component with your prescriber is worth doing if joints are a major concern.